Specifically, our findings underscore the potential of applying receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs) to the setting of MCC, as these agents have shown improved objective response rates and stable disease progression in cases of advanced MCC. Here, NTRK1 is linked to Merkel cell skin cancer.